Compare OCFC & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OCFC | AMPH |
|---|---|---|
| Founded | 1902 | 1996 |
| Country | United States | United States |
| Employees | 1007 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 971.8M |
| IPO Year | N/A | 2005 |
| Metric | OCFC | AMPH |
|---|---|---|
| Price | $18.20 | $17.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | $21.67 | ★ $28.38 |
| AVG Volume (30 Days) | ★ 601.9K | 466.6K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.24% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | N/A | ★ $719,887,000.00 |
| Revenue This Year | $47.51 | $6.90 |
| Revenue Next Year | $21.97 | $4.64 |
| P/E Ratio | ★ $16.71 | $131.43 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.09 | $17.03 |
| 52 Week High | $20.61 | $31.26 |
| Indicator | OCFC | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 41.33 | 30.67 |
| Support Level | $17.29 | $17.03 |
| Resistance Level | $18.62 | $20.08 |
| Average True Range (ATR) | 0.45 | 0.80 |
| MACD | -0.11 | -0.48 |
| Stochastic Oscillator | 19.87 | 2.19 |
OceanFirst Financial Corp is engaged in the banking sector of the United States. It conducts the business of attracting retail and business deposits and investing them in loans, consisting of single-family, owner-occupied residential mortgage loans, and commercial real estate loans. The company's sole segment deals with the delivery of loan and deposit products to customers. The bank's revenues are derived principally from interest on its loans, and to a lesser extent, interest on its investment and mortgage-backed securities. The rest of its income is dependent on bank card services and wealth management products and services.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.